75 results about "Carcinoma" patented technology

Set forth are vascular valves and servovalves and methods of using the same that may be positioned in the circulatory system without interrupting blood flow to facilitate solid organ transplantation so as to reduce graft organ anoxia and degradation before and after harvesting and storage, thereby minimizing late-term cardiac allograft vasculopathy as a major cause of graft failure. Along the urinary tract, bypassing bladder-generated urge sensation by diverting urine directly from the ureters to a neobladder or collection bag alleviates intractable incontinence, nocturia, urethral syndrome, overactive bladder, dysuria, or frequency. Where the lower tract is missing, a prosthesis can thwart disease and preclude the degenerative metaplastic transition to carcinoma risked when gut is used to construct a conduit for urine, a neobladder, and / or high-maintenance stoma. Druglines to valves and servovalves can directly pipeline-target medication to nidi, anastomoses, or any other trouble spots.

The invention provides a method of treating a colorectal carcinoma with a combination of an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody. In some aspects, the combination comprises 480 mg of each antibody such as, for example, 480 mg of an anti-LAG-3 antibody (e.g, relatlimab) and 480 mg of an anti-PD-1 antibody (e.g, nivolumab). In some aspects, the colorectal carcinoma is unresectable, advanced, or metastatic, including, for example, microsatellite stable or high microsatellite instable colorectal carcinoma.

The invention discloses a hepatocellular carcinoma postoperative early recurrence prediction method based on multi-modal fusion. The method comprises the following steps: firstly, integrating clinical data of a training set, a preoperative enhanced CT image and a postoperative full-view digital pathological image, and carrying out standardized correction; then, traditional image omics features and deep learning features are extracted from the CT image, cell nucleus morphological features and tumor microenvironment spatial configuration features are extracted from the pathological image, and key feature signatures are screened out through a maximum correlation minimum redundancy algorithm (mRMR) and LASSO regression in combination with clinical features. And then carrying out progressive model construction by adopting an XGBoost algorithm, sequentially establishing a clinical single-mode model, an image single-mode model, a pathological single-mode model and a multi-mode fusion model, and explaining and visualizing the models by utilizing an SHAP value and a Grad-CAM technology. Finally, the performance of the model is evaluated in a multi-dimensional mode through internal cross validation, foresight and external independent validation, risk layering is carried out based on the prediction probability, and individualized postoperative management is guided.

The invention relates to the field of intelligent medical treatment and artificial intelligence, and discloses an AI image recognition-based antral sinus cancer accompanied pyloric obstruction preoperative precise evaluation system, which comprises a data acquisition and preprocessing module for acquiring and preprocessing structured clinical data and multi-modal image data of a patient; the focus identification and segmentation module is used for carrying out focus identification and segmentation processing on the preprocessed image data by adopting an improved nnU-Net framework; the feature extraction and screening module is used for extracting image features from the segmentation result and screening features related to clinical indexes; the multi-modal feature fusion module is used for carrying out feature fusion on the screened image features and the preprocessed structured clinical data; the multi-task risk assessment module is used for establishing a multi-parameter risk prediction model by adopting a semi-structured distribution regression method and outputting a multi-task prediction result; and the evaluation report generation module is used for generating a structured evaluation report. And intelligent and precise preoperative evaluation and postoperative risk prediction of the antral carcinoma patient are realized.

Provided are an antibody-drug conjugate and a preparation method and a use thereof, which has a structure shown in the formula Ab-[M-L-E-D] x, the drug is selected from DNA topoisomerase inhibitors, the prepared antibody-drug conjugate has a relatively good drug-antibody conjugation ratio and has excellent targeted killing effects on solid tumors such as gastric cancer, breast cancer, lung cancer, and urothelium carcinoma.

Presented herein are systems and methods for detecting basal-cell carcinoma (BCC) in biomedical images of skin lesions. A computing system may identify, for a first subject at risk of BCC in a first lesion on a region of an epidermis: (i) a first biomedical image of an outer layer of the region on the epidermis of the first subject acquired in accordance with dermoscopy, and (ii) a plurality of second biomedical images of at least one inner layer in the region on the epidermis of the first subject acquired in accordance with reflection confocal microscopy (RCM). The computing system may apply the first biomedical image and the plurality of second biomedical images to a model architecture. The computing system may generate, based on applying to the model architecture, a score indicating a likelihood of BCC in the first lesion.

The invention discloses a risk prediction method of endometrial carcinoma, and relates to the field of risk prediction of endometrial carcinoma, and the method comprises the steps: accessing a multi-modal data set, and building a pathological multi-modal database; analyzing the pathological multi-modal database to obtain multi-modal characteristic data; establishing a prediction model, and comparing the performance of the prediction model to obtain a comparison result; according to the risk prediction model for the endometrial carcinoma, a prediction model is selected, a pathological data set is predicted, prediction data is obtained, and the model and a pathological multi-modal database are optimized in combination with a doctor feedback result. The technical problems of lack of a multi-modal prediction model, lack of a dynamic optimization mechanism of the risk prediction model of the endometrial carcinoma and lack of image and text data support of the risk prediction model of the endometrial carcinoma in the prior art are solved.

The invention discloses a gallbladder malignant tumor protein diagnosis biomarker combination, a kit and application. The protein marker provided by the invention comprises CA1 and / or IGFBP6 (insulin-like growth factor binding protein 6). According to the invention, an LC-MS / MS mass spectrometry method is adopted, mass spectrometry is carried out on a large number of clinical plasma samples, and by calculating log2 difference multiples of corresponding protein molecule contents in the plasma of a gallbladder cancer patient and the plasma of a normal person, it is determined that two protein molecules (CA1 protein and IGFBP6 protein) have good inspection benefits; the kit can be used as a marker for early diagnosis of gallbladder cancer; therefore, the invention provides a non-invasive screening means based on plasma, and the non-invasive screening means is used for predicting the cholecystic malignant tumor and distinguishing the cholecystic carcinoma crowd from the non-cancer crowd. And materials are convenient to take, the blood sample amount is small, and the sensitivity is high. The invention can fill the blank that no protein marker combination with high diagnostic efficiency exists at present for the cholecystic malignant tumor, and has great clinical significance.

The invention discloses a method for accurately identifying benign and malignant cells based on multi-dimensional characteristics of a single cell transcriptome, and belongs to the technical fields of bioinformatics, tumor molecular biology and cell identification. On the basis of single cell transcriptome sequencing data of tumor tissues and para-carcinoma tissues, three types of information including copy number variation, allele specific copy number variation and tumor-related transcriptional characteristics are synthesized, and final benign and malignant identification is performed on each EpCAM positive epithelial cell through a multi-evidence voting strategy. The method disclosed by the invention has relatively high stability and accuracy in a multi-patient, multi-sample and early tumor scene, particularly improves the recognition capability of early lesion and malignant cells in benign and malignant boundary transition state cells, and provides a reliable technical means for precise diagnosis and individualized treatment of tumors.

The utility model discloses a portable sampling device for endometrial cancer gene methylation detection in the technical field of sampling devices, which comprises an extraction cylinder, one end of the extraction cylinder is fixedly inserted with a connecting pipe, the inner wall of the connecting pipe is movably inserted with a detachable extraction pipe, and the inner wall of the detachable extraction pipe is movably inserted with a connecting pipe. A plurality of guide blocks are fixedly arranged on the outer wall of the end, inserted into the connecting pipe, of the detachable extraction pipe, the guide blocks are in sliding fit with the inner wall of the connecting pipe, and two toothed plate sealing pieces used for blocking the connecting pipe are movably arranged on the inner wall of the extraction cylinder; after the device is used, the grab handle is firstly detached, then the detachable extraction pipe is detached, and at the moment, the guide block slides along the inner wall of the connecting pipe, so that the connecting pipe drives the transmission gear to rotate reversely, and the two toothed plate sealing pieces are reset along with the reverse rotation of the transmission gear to seal the connecting pipe; therefore, the possibility that external sundries enter the extraction barrel through the connecting pipe when the device is not used is reduced.

A method of treating cancer involves administering a combination of activators comprising a therapeutically effective dose of acylfluben or a pharmaceutically acceptable salt thereof and a therapeutically effective dose of an anti-CD20 antibody. The anti-CD20 antibody can be selected from rituximab, obinutuzumab, ofatumumab, and tocitumomab. The cancer may be a B-cell carcinoma.

The present invention proposes the inhibition of the catalytic function of the SWI / SNF complex in patients with NUT carcinoma, to promote the differentiation and specific death of tumour cells. Specifically, inhibitors of the activity of the SMARCA4 and / or SMARCA2 catalytic subunits of the SWI / SNF complex, for the use thereof in the treatment of NUT carcinoma, are described.

The invention discloses a pre-diagnosis information processing system based on large model intrahepatic bile duct stone cancerization, which belongs to the field of intrahepatic bile duct stone cancerization, and comprises a data acquisition module for acquiring character data of a patient to form a structured data packet, and a pre-diagnosis information processing module for processing pre-diagnosis information based on an unstructured text input to the patient, the NLP analysis module is used for establishing a sequential clinical basic file and is used for collecting multi-source data of a patient; the multi-modal receiving module is used for forming a complete file in combination with a clinical basic file; the intelligent diagnosis and analysis module is used for receiving the complete file and performing sequential analysis; the grading and decision-making module is used for automatically matching preset action suggestions according to parameters output by the intelligent diagnosis and analysis module; the multimodal data is fused, the dynamic time sequence analysis function is performed, and the pre-diagnosis function focuses on pre-diagnosis of intrahepatic bile duct stone cancerization.

The present invention relates to an antibody or fragment thereof specifically binding to meningeosis carcinoma-specific antigen, such as DDX53, KIF3C, and AKR1A1, an anti-body or fragment thereof for use in the prophylaxis and / or treatment of cancer, preferably melanoma, further preferably melanoma with leptomeningeal spread, highly preferably melanoma with meningeosis carcinomatosa, a pharmaceutical composition comprising said antibody or fragment thereof, a nucleic acid encoding said antibody or fragment thereof, a vector comprising said nucleic acid, a prokaryotic or eukaryotic host cell comprising said vector, and to a method for the prophylaxis and / or treatment of cancer, preferably melanoma, further preferably melanoma with leptomeningeal spread, highly preferably melanoma with meningeosis carcinomatosa, in a living being, comprising the admin- istration of a prophylactically and / or therapeutically effective amount of said antibody or fragment thereof or said pharmaceutical composition.

The invention discloses an application of a DHCR7 inhibitor in enhancing the drug sensitivity of mitartan. The DHCR7 gene related to the adrenal cortical carcinoma is obtained through machine learning screening, cell experiments verify that knock-down of the DHCR7 can enhance the sensitivity of a subject to mitartan, and a new research strategy and a treatment target are provided for treatment of the adrenal cortical carcinoma.

The invention relates to the technical field of diagnosis, in particular to a prognosis evaluation kit and evaluation method for renal cell carcinoma patients based on DNAJA1 protein expression quantity. The method for evaluating the prognosis and immune microenvironment state of the RCC patient based on the DNAJA1 expression level provided by the invention has good stability, accuracy and operability, can realize hierarchical management and individualized treatment guidance of patient risks, and has remarkable clinical and social values.

Proposed are a sessile droplet biosensor and an extracellular vesicle detection method using same, wherein the sessile droplet biosensor can easily and conveniently perform superbright staining of proteins or lipids in extracellular vesicles through a non-specific staining material, such as CFSE, without a complicated signal generation process and can concentrate extracellular vesicles to a high concentration at the edges of sessile droplets by internal flowing induced by non-uniform evaporation in the sessile droplets, thereby detecting extracellular vesicles with high sensitivity. Moreover, the extracellular vesicle detection method using the sessile droplet biosensor can be utilized for standard setting technology for various diseases, such as cancer diagnosis standard setting technology, by the analysis of extracellular vesicle staining signals, or an information providing method for the analysis of extracellular vesicle staining signals can be utilized for early diagnosis of various diseases such as cancer, evaluation of prognosis for treatment, and screening for carcinoma.

This invention is directed to methods of reducing incidence or reducing severity or preventing progression of or preventing or treating or preventing pathogenesis of a cancer in a subject, wherein said subject is predisposed to, showing early indications of or suffering from cancer, or methods of reducing intracellular bacterial infection in subjects at risk for or suffering from carcinoma, or from pre-neoplastic or metaplastic tissue changes, comprising contacting at least one cell in an affected tissue in said subject with an agent reducing intracellular bacterial infection in affected tissue, reducing localization of intracellular bacteria proximally to nuclei in cells of affected tissue, or a combination thereof. This invention is further directed to methods of personalized optimized diagnosis and therapy in a subject, comprising screening a subject predisposed to, or at risk for cancer and identifying whether the pre-cancerous or cancerous tissue in the subject is intracellularly infected with bacteria, optionally assessing the intracellular localization of the bacteria-containing compartment to determine a distance of same from a nucleus in the cell; optionally assessing the oncogene profile expression in the subject, and further scoring the subject in terms of the prognosis and potential for therapy and then treating the subject to reduce the intracellular bacterial burden, promote re-localization of the bacterial compartment to be at a further distance from the nucleus, successfully eradicate intracellular bacterial infection, prevent or reduce cell-to-cell spread of the bacteria or any combination thereof. Compositions and kits for effecting the methods of this invention are also provided. This invention still further provides a system for identifying patients who would benefit from adjunctive antimicrobial therapies, enhancing treatment outcomes by providing comprehensive microbial feature characterization, including spatial localization of key microbes associated with treatment resistance in an integrated platform with advanced machine learning algorithms, ultimately providing a personalized patient assessment, enhancing treatment outcomes and optimizing therapeutic strategies.

The compositions provided herein including embodiments thereof include, inter alia, TGF-beta-binding agents that bind to TGF-beta in its active / mature form (i.e., active TGF-beta, mature TGF-beta). Further provided are methods of treatment including, inter alia, administering to a patient a diagnostic and a therapeutic TGF-beta-binding agents both including a radioisotope. The compositions and methods provided herein are, inter alia, useful as theranostics for the treatment of cancer (e.g., solid tumors such as carcinoma or sarcoma).

The present invention relates to pharmaceutical compositions and methods for the treatment of carcinomas and sarcomas. In particular, the invention provides a pharmaceutical composition comprising a peptide or pharmaceutically acceptable salt thereof for use in treating a carcinoma or a sarcoma in a human subject, wherein the peptide comprises an amino acid sequence as set forth in SEQ ID NO: 1 and a cell penetrating peptide and wherein the pharmaceutical composition is systemically administered to the subject weekly to provide a dose of the peptide of about 15-65 mg / m2 body surface area (BSA) per week, calculated as the free form of the peptide.

A method of treating cancer cells includes contacting the cancer cells with a CoO / CaSiO3@g-C3N4 nanocomposite material. The CoO / CaSiO3@g-C3N4 nanocomposite material includes hexagonal metal oxide nanoparticles comprising a CoO phase and a CaSiO3 phase dispersed on a matrix of g-C3N4 nanosheets. The hexagonal metal oxide nanoparticles have an average particle diameter in a range from 340 to 440 nm. The CoO / CaSiO3@g-C3N4 nanocomposite material has a percent inhibition for Human Breast Carcinoma (MCF-7) cells at least 55% inhibition in an in-vitro cellular viability assay.

The application discloses application of an HTRA1 inhibitor in preparation of a drug for treating pancreatitis-cancer transformation, and belongs to the technical field of medicines.The HTRA1 inhibitor is screened through a drug database, the HTRA1 inhibitor is used to treat a pancreatic cancer cell line and a mouse pancreatitis-cancer transformation in-vivo model, it is proved that the HTRA1 inhibitor Carfilzomib can inhibit the malignant phenotype of Panc1 cells in vitro, and can inhibit the transformation of a KC mouse stimulated by cerulean into a pancreatic ductal adenocarcinoma in vivo, and the application provides a basis for using the HTRA1 inhibitor as the drug for treating pancreatitis-cancer transformation.

This invention discloses a high-performance computing-based system and method for evaluating colorectal cancer screening strategies, belonging to the field of medical information processing technology. It includes: a dual-pathway disease model module supporting both adenoma-carcinoma pathways and serrated adenoma pathways, modeled using age-dependent normal distribution progression time; an individualized risk scoring module integrating risk factors such as family history, inflammatory bowel disease, obesity, and diabetes; a screening strategy simulation module supporting combined screening strategies using different tools, employing compliance parameters specific to the Chinese urban population; a high-performance computing module using Numba JIT compilation technology for acceleration, multi-process parallel processing for further acceleration, and data structure optimization such as integer age to reduce memory usage; and a health economics evaluation module calculating indicators such as QALY, LYG, and ICER. This invention achieves significant performance improvements while maintaining model accuracy, greatly reducing simulation time for large-scale populations.

The present disclosure provides a targeted B7-H3 single-domain antibody, a chimeric antigen receptor molecule, a chimeric antigen receptor cell, and their application in the preparation of drugs for treating nasopharyngeal carcinoma, which belongs to the field of antibody drug technology; an amino acid sequence of the B7-H3 targeted single-domain antibody provided by the present disclosure is shown in SEQ ID No. 1, and an amino acid sequence of the chimeric antigen receptor molecule is shown in SEQ ID No. 2; the chimeric antigen receptor cell provided by the present disclosure can specifically bind to tumor cells through targeting B7-H3 and exert specific antitumor effects via antigen-dependent mechanism, making it one of the potential effective methods for treating recurrent and metastatic NPC; according to the records of the embodiments, after co-culturing the chimeric antigen receptor cell provided by the present disclosure with the nasopharyngeal carcinoma cell line HK1-EBV, it can significantly kill nasopharyngeal carcinoma cell.

The present invention concerns a new pharmaceutical composition with less than 10 EU (endotoxin unit) per mL of composition (UE / mL) and comprising an imaging agent consisting of a conjugate of 1) a polypeptide A38C having the amino acid sequence SEQ ID NO:1 with 2) a near Infra-red (IR) fluorophore, and its uses for performing image guided diagnosis and surgery respectively on a subject.

The present invention belongs to the technical field of diagnosis, and particularly relates to a marker for differentiating carcinomas of the colon and rectum from adenomas of the colon and rectum and the use thereof. Disclosed in the present invention is one or more of 75 markers as a marker for distinguishing carcinomas of the colon and rectum from adenomas of the colon and rectum. By means of detecting the content, expression level, and / or activity of the above markers, differentiation of carcinomas of the colon and rectum from adenomas of the colon and rectum can be achieved.

The invention discloses a preparation method of a medicine for treating ovarian cancer and endometrial carcinoma and the medicine for treating the ovarian cancer and the endometrial carcinoma. The invention belongs to the technical field of medicine preparation, and aims to solve the problem of preparation of medicines for treating ovarian cancer and endometrial carcinoma, polyoxyethylene hydrogenated castor oil 40, 1, 2-propylene glycol and ethyl oleate are adopted to construct a self-emulsifying medicine delivery system to prepare polyphyllin-I nanoparticles, and then the medicines are prepared, so that the bioavailability and targeting property of the medicines are improved. Aiming at the problems of poor curative effect and large side effect when the existing medicine is used for treating ovarian cancer and endometrial carcinoma, the medicine can be prepared by combining polyphyllin-I nanoparticles and rapamycin.

The present invention provides an in vitro method for detecting immuno-suppressive fibroblasts, in particular cancer-associated fibroblasts (CAFs), in a cancerous sample from a subject suffering from a carcinoma, the method comprising detecting ANTXR1 + fibroblasts in a cancerous sample from this patient.SOLUTION: The present invention also relates to an in vitro method for predicting the response of a subject suffering from cancers to an immunotherapeutic treatment, an immunotherapeutic treatment for use in treating cancers in patients, the use of ANTXR1 as a biomarker for the identification of immunosuppressive fibroblasts, in particular immunosuppressive CAFs, an agent targeting ANTXR1 + fibroblasts for use in treating cancers in patients, an article of manufacture or a kit comprising a) an agent targeting ANTXR1 + fibroblasts and b) an immunotherapeutic treatment.SELECTED DRAWING: None

The present disclosure relates to a chimeric adenovirus for detecting circulating tumor cells. An adenovirus type 5 / 3 for detecting circulating tumor cells, according to the present disclosure, comprises a knob domain of adenovirus type 3 and thus targets DSG2, and thus can also detect EMT circulating tumor cells, has excellent viability in the blood, and can accurately detect and isolate circulating tumor cells from more carcinomas, and thus enables early diagnosis of cancer and analysis of the type and stage of primary cancer, and can predict cancer prognosis, monitor cancer progression and analyze drug response and therapeutic effects through the genetic analysis of isolated circulating tumor cells, and therefore can be effectively used in personalized treatment.